EMEA-002554-PIP02-19

EMEA-003521-PIP01-23

Referral: Ipidacrine-containing medicinal products, ipidacrine Article 31 referrals Under evaluation, 14/11/2025

Human medicines European public assessment report (EPAR): Comirnaty, COVID-19 mRNA vaccine, Date of authorisation: 21/12/2020, Revision: 57, Status: Authorised

Human medicines European public assessment report (EPAR): Anagrelide Viatris (previously Anagrelide Mylan), anagrelide, Date of authorisation: 15/02/2018, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Tukysa, tucatinib, Date of authorisation: 11/02/2021, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Elucirem, gadopiclenol, Date of authorisation: 07/12/2023, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Ondexxya, andexanet alfa, Date of authorisation: 26/04/2019, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Plegridy, peginterferon beta-1a, Date of authorisation: 18/07/2014, Revision: 28, Status: Authorised

Incident management plan